BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BLU-5937 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BLU-5937\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07519395-1312@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270309
DTEND;VALUE=DATE:20270310
SUMMARY:BLU-5937: Phase 2 readout est. (NCT07519395)
DESCRIPTION:BLU-5937\, phase 2\, Irritable Bowel Syndrome.\nStudy: A Study 
 to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo i
 n Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bo
 wel Syndrome - Mixed (IBS-M)\nEstimated primary completion: 9 March 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/blu-5937#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07519395
URL:https://assetmemo.bio/drug/blu-5937#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07650084-1312@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270827
DTEND;VALUE=DATE:20270828
SUMMARY:BLU-5937: Phase 3 readout est. (NCT07650084)
DESCRIPTION:BLU-5937\, phase 3.\nStudy: A 24-Week Study of the Efficacy and
  Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extens
 ion\nEstimated primary completion: 27 August 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/blu-5937#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07650084
URL:https://assetmemo.bio/drug/blu-5937#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
